Associate Director, StatisticsTakeda Development Center Americas, Inc.Cambridge, Massachusetts, United States
PB0502 - Clinical outcomes in patients with hemophilia A receiving octocog alfa or rurioctocog alfa pegol versus other FVIII replacement therapies: Insights from the AHEAD, CHESS II, and CHESS PAEDs studies
Monday, June 24, 202413:45 – 14:45 ICT
PB0549 - Physical activity engagement and health-related quality of life in patients with hemophilia A receiving either octocog alfa or rurioctocog alfa pegol versus other FVIII replacement therapies
